1. Home
  2. IIPR vs MLYS Comparison

IIPR vs MLYS Comparison

Compare IIPR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innovative Industrial Properties Inc.

IIPR

Innovative Industrial Properties Inc.

HOLD

Current Price

$54.50

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$20.59

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IIPR
MLYS
Founded
2016
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.9B
IPO Year
2016
2023

Fundamental Metrics

Financial Performance
Metric
IIPR
MLYS
Price
$54.50
$20.59
Analyst Decision
Hold
Strong Buy
Analyst Count
7
11
Target Price
★ $61.45
$46.33
AVG Volume (30 Days)
385.7K
★ 1.2M
Earning Date
11-02-2026
11-09-2026
Dividend Yield
★ 13.93%
N/A
EPS Growth
N/A
★ 37.43
EPS
★ 2.39
N/A
Revenue
★ $265,955,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.40
N/A
P/E Ratio
$22.87
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$44.58
$20.12
52 Week High
$65.38
$47.65

Technical Indicators

Market Signals
Indicator
IIPR
MLYS
Relative Strength Index (RSI) 55.64 36.80
Support Level $54.00 $20.12
Resistance Level $57.85 $31.19
Average True Range (ATR) 1.26 1.24
MACD 0.49 0.01
Stochastic Oscillator 94.01 13.34

Price Performance

Historical Comparison
IIPR
MLYS

About IIPR Innovative Industrial Properties Inc.

Innovative Industrial Properties Inc is a real estate investment trust focused on the acquisition, ownership and management of specialized industrial and commercial properties in the United States. Its properties are prominently leased to state-licensed operators for their regulated cannabis facilities. The company conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by its Operating Partnership, directly or through subsidiaries. Its segments are: Cannabis Portfolio and Life Science Portfolio, with the majority of revenue coming from the Cannabis Portfolio segment, which involves acquiring, developing, and leasing real estate to regulated cannabis operators on long-term triple-net leases.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: